证券代码：300255 证券简称：常山药业 公告编号：2025-42 第六届监事会第四次会议决议公告 本公司及其监事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 河北常山生化药业股份有限公司（以下简称"公司"）第六届监事会第四次 会议于2025年10月29日在公司办公楼会议室以现场方式召开。本次会议于2025 年 10 月 19 日以邮件或直接送达的方式确保每一位监事收到本次会议通知。与会 的各位监事均已知悉与所议事项相关的必要信息。会议应参与表决监事 3 名，实 际参与表决监事 3 名。本次会议由公司监事会主席宗庆松先生主持，符合《公司 法》及《公司章程》等规定。 二、监事会会议审议情况 河北常山生化药业股份有限公司 1．审议通过《关于<公司 2025 年第三季度报告>的议案》 监事会认为董事会编制和审核公司 2025 年第三季度报告的程序符合法律、 行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的实际 情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：3 票同意；0 票反对；0 票弃权。 三、备查文件 1．第六届 ...

Financial Performance - Q3 2025 revenue was CNY 189,613,515.77, a decrease of 12.32% year-over-year[4] - Net profit attributable to shareholders was CNY -15,728,432.84, down 129.02% compared to the same period last year[4] - Basic and diluted earnings per share were both CNY -0.02, reflecting a decline of 133.33% year-over-year[4] - Total operating revenue decreased to ¥681,221,459.23 from ¥784,021,902.08, representing a decline of approximately 13.1% year-over-year[19] - Net profit for the period was -¥56,983,632.04, compared to -¥27,806,023.52 in the previous period, indicating a worsening of approximately 104.1%[20] - The total comprehensive income for the period was -¥57,237,822.00, compared to -¥27,804,018.75 in the previous period, indicating a decline of approximately 106.5%[20] - The company reported a basic earnings per share of -¥0.05, compared to ¥0.01 in the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,657,584,588.98, an increase of 2.98% from the end of the previous year[4] - The total assets of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. as of September 30, 2025, amounted to CNY 4,657,584,588.98, an increase from CNY 4,522,760,540.58 at the beginning of the period[16] - Current assets totaled CNY 2,077,304,073.35, up from CNY 2,002,412,631.48 at the beginning of the period, reflecting a growth of approximately 3.9%[16] - Total liabilities rose to CNY 3,179,083,140.13 from CNY 2,987,021,269.73, reflecting an increase of about 6.4%[17] - The company's equity remained stable with total equity at CNY 1,478,501,448.85, unchanged from the previous period[17] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 142,350,749.85, down 5.32%[4] - Cash flow from operating activities generated ¥142,350,749.85, down from ¥150,346,631.17, a decrease of about 5.3% year-over-year[21] - Cash flow from investing activities increased by 39.04% year-over-year, mainly due to reduced cash payments for fixed assets and other long-term assets[10] - Net cash flow from investing activities was -$72.1 million, an improvement from -$118.3 million year-over-year[22] - Cash inflow from financing activities totaled $2.07 billion, compared to $1.71 billion in the previous year[22] - Cash outflow from financing activities was $2.13 billion, up from $1.65 billion year-over-year[22] - Net cash flow from financing activities was -$61.9 million, a decline from a positive $51.0 million in the previous year[22] - The net increase in cash and cash equivalents was $11.2 million, down from $83.3 million year-over-year[22] - The ending balance of cash and cash equivalents was $247.0 million, compared to $314.2 million at the end of the previous year[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 46,618[11] Strategic Focus - The company plans to continue focusing on R&D for new products and technologies to enhance market competitiveness[15] - Future guidance indicates a strategic emphasis on market expansion and potential mergers and acquisitions to drive growth[15] Operational Efficiency - Sales expenses decreased by 64.22% year-over-year, attributed to the inclusion of products in national procurement and adjustments in sales strategy[9] - Investment income increased by 100.00% year-over-year due to gains from the disposal of a subsidiary[9] - Research and development expenses increased slightly to ¥24,568,492.79 from ¥23,438,244.55, reflecting a growth of approximately 4.8%[19] - Other income decreased significantly to ¥5,567,369.76 from ¥30,589,042.11, a decline of about 81.8% year-over-year[19] - The company recorded credit impairment losses of ¥7,201,497.18, up from ¥531,492.70, marking an increase of approximately 1255.5% year-over-year[20] Inventory and Receivables - Accounts receivable rose to CNY 310,502,510.21 from CNY 253,625,332.05, indicating an increase of approximately 22.4%[16] - Inventory decreased to CNY 1,341,817,413.22 from CNY 1,385,747,770.05, showing a decline of about 3.2%[16] Borrowings - Short-term borrowings increased by 47.98% compared to the beginning of the period, indicating a rise in borrowing[7] - Short-term borrowings increased significantly to CNY 1,313,433,777.78 from CNY 887,546,719.51, marking an increase of approximately 48.0%[17] Audit Status - The third quarter financial report was not audited[23]

Core Points - The Shanghai Composite Index closed at 3991.35 points, above the five-day moving average, with an increase of 1.04% [1] - The total trading volume of A-shares reached 1,576.01 billion yuan [1] - A total of 722 A-shares have prices that surpassed the five-day moving average, indicating a positive market trend [1] Summary by Category Stock Performance - Notable stocks with significant deviations from the five-day moving average include Longzhu Technology (15.40%), Yongfu Co., Ltd. (14.16%), and Pioneer New Materials (13.24%) [1] - Longzhu Technology saw a daily increase of 20.22%, with a turnover rate of 12.58% [1] - Yongfu Co., Ltd. increased by 19.98%, with a turnover rate of 9.37% [1] - Pioneer New Materials rose by 18.01%, with a turnover rate of 27.91% [1] Market Trends - Stocks with smaller deviations from the five-day moving average include Aibulu, Xinhua Medical, and Yunnan Baiyao, which have just crossed the five-day moving average [1] - The overall market sentiment appears to be bullish, as indicated by the number of stocks surpassing their five-day moving averages [1] Trading Data - The trading data for stocks that broke the five-day moving average includes various metrics such as daily price changes, turnover rates, and the latest prices compared to the five-day moving average [1][2] - The table provided lists multiple stocks with their respective performance metrics, highlighting the active trading environment [2]

Group 1 - The company, Changshan Pharmaceutical, stated on October 21 that it will announce any significant progress regarding the上市申请 (listing application) for Aibennapeptide according to relevant regulations [2]

Group 1 - The company, Changshan Pharmaceutical, reported that as of October 20, 2025, the number of its shareholders is 45,431 [2]

Core Insights - The stock price of Changshan Pharmaceutical has increased by 160.63% year-to-date, with a recent rise of 7.36% over the last five trading days [2] - The company has a market capitalization of 47.883 billion yuan and reported a trading volume of 7.47 billion yuan on October 21 [1] - Changshan Pharmaceutical's main business includes the research, production, and sales of heparin series products, with revenue composition of 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other sources [2] Financial Performance - For the first half of 2025, Changshan Pharmaceutical achieved operating revenue of 492 million yuan, a year-on-year decrease of 13.42%, while the net profit attributable to the parent company was -29.09 million yuan, an increase of 37.98% year-on-year [2] - The company has distributed a total of 181 million yuan in dividends since its A-share listing, with 4.5953 million yuan distributed over the last three years [3] Shareholder Information - As of October 10, 2023, the number of shareholders for Changshan Pharmaceutical was 45,700, a decrease of 2.04% from the previous period, with an average of 20,094 circulating shares per person, an increase of 2.08% [2] - Hong Kong Central Clearing Limited is the fourth largest circulating shareholder, holding 10.5521 million shares, an increase of 8.0391 million shares from the previous period [3]

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Changshan Pharmaceutical, including stock price movements and trading volumes [1][2] - On October 20, Changshan Pharmaceutical's stock rose by 4.60%, with a trading volume of 1.415 billion yuan, and a net financing purchase of 37.36 million yuan [1] - As of October 20, the total margin balance for Changshan Pharmaceutical reached 2.088 billion yuan, accounting for 4.46% of its market capitalization, indicating a high level of financing activity [1] Group 2 - As of October 10, the number of shareholders for Changshan Pharmaceutical was 45,700, a decrease of 2.04%, while the average circulating shares per person increased by 2.08% to 20,094 shares [2] - For the first half of 2025, Changshan Pharmaceutical reported a revenue of 492 million yuan, a year-on-year decrease of 13.42%, and a net profit attributable to shareholders of -29.09 million yuan, reflecting a year-on-year increase of 37.98% in losses [2] - The company has distributed a total of 181 million yuan in dividends since its A-share listing, with 4.5953 million yuan distributed over the past three years [3]

Market Overview - The chemical pharmaceutical sector increased by 0.32% on October 20, with Fuxiang Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Top Gainers - Fuxiang Pharmaceutical (300497) closed at 10.48, up 5.43% with a trading volume of 302,100 shares and a transaction value of 316 million [1] - Changshan Pharmaceutical (300255) closed at 50.98, up 4.60% with a trading volume of 280,800 shares [1] - Kelong Pharmaceutical (002422) closed at 36.47, up 4.56% with a trading volume of 188,600 shares and a transaction value of 681 million [1] Top Losers - Anglikang (002940) closed at 41.66, down 7.05% with a trading volume of 214,800 shares [2] - Asia-Pacific Pharmaceutical (002370) closed at 7.35, down 5.16% with a trading volume of 1,918,400 shares [2] - Yifan Pharmaceutical (002019) closed at 13.11, down 4.45% with a trading volume of 271,200 shares and a transaction value of 358 million [2] Fund Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 623 million from institutional investors, while retail investors saw a net inflow of 672 million [2] - The top stock with the highest net inflow from institutional investors was Xingqi Eye Medicine (300573) with 206 million [3] - Kelong Pharmaceutical (002422) had a net inflow of 99.67 million from institutional investors [3]

Group 1 - The core viewpoint is that the A-share innovative drug concept stocks are experiencing a significant upward trend, with notable increases in stock prices for several companies [1] - Iwubio has seen a rise of over 10% in its stock price [1] - Haoyuan Pharmaceutical has increased by over 9% [1] - Other companies such as Fuxiang Pharmaceutical, Changshan Pharmaceutical, and Medici have also shown upward movement in their stock prices [1]

Group 1 - The core point of the news is that Changshan Pharmaceutical experienced a stock price increase of 5.13%, reaching 51.24 CNY per share, with a trading volume of 543 million CNY and a turnover rate of 1.20%, resulting in a total market capitalization of 47.093 billion CNY [1] - Changshan Pharmaceutical, established on September 28, 2000, and listed on August 19, 2011, is primarily engaged in the research, production, and sales of heparin series products, with main business revenue composition being 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other products [1] Group 2 - From the perspective of fund holdings, one fund under E Fund has a significant position in Changshan Pharmaceutical, with the E Fund Growth ETF (159572) holding 352,200 shares, accounting for 2.07% of the fund's net value, making it the largest holding [2] - The E Fund Growth ETF (159572) was established on December 15, 2023, with a latest scale of 792 million CNY, and has achieved a year-to-date return of 20.12%, ranking 2291 out of 4218 in its category, and a one-year return of 25.61%, ranking 2080 out of 3865 [2]